NCT05198843: Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer (IBC)
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have metastases accessible for biopsy
Exclusions: Patients without one standard regimen exposure in a metastatic setting; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease

Comments are closed.

Up ↑